Quoin Pharmaceuticals Ltd.

Azrieli Center, Round Tower, 30th Floor

132 Menachem Begin Blvd

Tel Aviv, 6701101

 

August 4, 2022 

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Christine Westbrook

 

RE:

Quoin Pharmaceuticals Ltd. Registration Statement on Form F-1 Registration No. 333-266476

 

Ladies and Gentlemen:

 

Quoin Pharmaceuticals Ltd. (the “Company”) hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effective date of the above-referenced Registration Statement, as amended, so that such Registration Statement, as amended, will become effective at 9:00 a.m., Eastern Time, on Friday, August 5, 2022, or as soon thereafter as practicable.

 

[Signature Page Follows]

 

 

	Very truly yours,
	QUOIN PHARMACEUTICALS LTD.
	By:	/s/ Dr. Michael Myers
		Name: Dr. Michael Myers
		Title: Chief Executive Officer